Open Access

ARTICLE

miR-632 Promotes Laryngeal Carcinoma Cell Proliferation, Migration, and Invasion Through Negative Regulation of GSK3b

by

* Department of Otorhinolaryngology, Renmin Hospital of Wuhan University, Wuhan, Hubei, P.R. China
† Department of Otorhinolaryngology, Liaocheng People’s Hospital, Liaocheng, Shandong, P.R. China
‡ Department of Oncology, Liaocheng Tumor Hospital, Liaocheng, Shandong, P.R. China

Oncology Research 2020, 28(1), 21-31. https://doi.org/10.3727/096504018X15213142076069

Abstract

Laryngeal cancer, one of the most common head and neck malignancies, is an aggressive neoplasm. Increasing evidence has demonstrated that microRNAs (miRNAs) exert important roles in oncogenesis and progression of diverse types of human cancers. miR-632, a tumor-related miRNA, has been reported to be dysregulated and implicated in human malignancies; however, its biological role in laryngeal carcinoma remains to be elucidated. The present study aimed at exploring the role of miR-632 in laryngeal cancer and clarifying the potential molecular mechanisms involved. In the current study, miR-632 was found to be significantly upregulated both in laryngeal cancer tissues and laryngeal cancer cell lines. Functional studies demonstrated that miR-632 accelerated cell proliferation and colony formation, facilitated cell migration and invasion, and enhanced the expression of cell proliferation-associated proteins, cyclin D1 and c-myc. Notably, miR-632 could directly bind to the 3 -untranslated region (3 -UTR) of glycogen synthase kinase 3 (GSK3 ) to suppress its expression in laryngeal cancer cells. Mechanical studies revealed that miR-632 promoted laryngeal cancer cell proliferation, migration, and invasion through negative modulation of GSK3 . Pearson’s correlation analysis revealed that miR-632 expression was inversely correlated with GSK3 mRNA expression in laryngeal cancer tissues. Taken together, our findings suggest that miR-632 functions as an oncogene in laryngeal cancer and may be used as a novel therapeutic target for laryngeal cancer.

---

Keywords

---